Regulation of expression of the endothelial cell nitric oxide synthase

Clinical and Experimental Pharmacology and Physiology

Volumn 23, Issue 3, 1996, Pages 251-255

  Harrison, David G ^a,b   Sayegh, Hassan ^a   Ohara, Yuichi ^a   Inoue, Nobutaka ^a   Venema, Richard C ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Division of Cardiology   (United States)

Author keywords

growth; shear stress; Sp1; transforming growth factor beta

Indexed keywords

CHELERYTHRINE; NITRIC OXIDE SYNTHASE; PHORBOL ESTER; STAUROSPORINE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ATHEROSCLEROSIS; CONFERENCE PAPER; CONTROLLED STUDY; COW; CYTOLOGY; MOLECULAR BIOLOGY; NONHUMAN; SHEAR STRESS; VASCULAR ENDOTHELIUM;

EID: 0029884947     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1681.1996.tb02606.x     Document Type: Conference Paper

References (36)

1. Furchgott RF, Zawadski JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 228: 373-6.
2. Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature (Lond.) 1987; 327: 524-6.
3. Hintze TH, Vatner SF. Reactive dilation of large coronary arteries in conscious dogs. Circ. Res. 1984; 54: 50-7.
4. Holtz J, Förstermann U, Pohl U, Giesler M, Bassenge E. Flow-dependent, endothelium-mediated dilation of epicardial coronary arteries in conscious dogs: Effects of cyclooxygenase inhibition. J. Cardiovasc. Pharmacol. 1984; 6: 1161-9.
5. Rubanyi GM, Romero JC, Vanhoutte PM. Flow-induced release of the endothelium-derived relaxing factor. Am. J. Physiol. (Heart Circ. Physiol) 1986; 259: H1145-9.
6. Miller VM, Vanhoutte PM. Enhanced release of endothelium-derived factor(s) by chronic increases in blood flow. Am. J. Physiol. (Heart Circ. Physiol.) 1988; 255: H446-51.
7. Nishida K, Harrison DG, Navas JP et al. Molecular cloning and characterization of the constitutive bovine aortic endothelial cell nitric oxide synthase. J. Clin. Invest. 1992; 90: 2092-6.
8. Uemetsu M, Ohara Y, Navas JP et al. Regulation of endothelial cell nitric oxide synthase mRNA expression by shear stress. Am. J. Physiol. (Cell Physiol.) 1995; 38: C1371-8.
9. Sullivan MJ, Higginbotham MB, Cobb FR. Exercise training in patients with severe left ventricular dysfunction. Hemodynamic and metabolic effects. Circulation 1988; 78: 506-15.
10. Sessa WC, Pritchard K, Seyedi N, Wang J, Hintze TH. Chronic exercise in dogs increases coronary vascular nitric oxide production and endothelial cell nitric oxide synthase gene expression. Circ. Res. 1994; 74: 349-53.
11. Kaiser L, Spickard RC, Olivier NB. Heart failure depresses endothelium dependent responses in canine femoral artery. Am. J. Physiol. 1989; 256: H962-7.
12. Kubo SH, Rector TS, Bank AJ, Williams RE, Heifetz SM. Endothelium dependent vasodilation is attenuated in patients with heart failure. Circulation 1991; 84: 1589-96.
13. Sellke FW, Quillen JE, Brooks LA, Harrison DG. Endothelial modulation of the coronary vasculature in vessels perfused via mature collaterals. Circulation 1990; 81: 1938-47.
14. Arnal J-F, Yamin J, Dockery S, Harrison DG. Regulation of endothelial nitric oxide synthase mRNA, protein and activity during cell growth. Am. J. Physiol. (Cell Physiol.) 1994; 267 (Cell Physiol. 36): C1381-8.
15. Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J. Clin. Invest. 1989; 83: 1774-7.
16. Garg UC, Hassid A. Nitric oxide-generating vasodilators inhibit mitogenesis and proliferation of BALB/C 3T3 fibroblasts by a cyclic GMP-independent mechanism. Biochem. Biophys. Res. Commun. 1990; 171: 474-9.
17. Yoshizumi M, Perrella MA, Burnett JC, Lee M-E. Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ. Res. 1993; 73: 205-9.
18. Liao JK, Shin WS, Lee WY, Clark SL. Oxidized low-density lipoprotein decreases the expression of endothelial nitric oxide synthase. J. Biol. Chem. 1995; 270: 319-24.
19. McQuillan LP, Leung GK, Marsden PA, Kostyk SK, Kourembanas S. Hypoxia inhibits expression of eNOS via transcriptional and posttranscriptional mechanisms [erratum published in Am. J. Physiol. 1995; 268: section H]. Am. J. Physiol, 1994; 267: H1921-7.
20. Venema RC, Nishida K, Alexander RW, Harrison DG, Murphy TJ. Organization of the bovine gene encoding the endothelial nitric oxide synthase. Biochim. Biophys. Acta 1994; 1218: 1-8.
21. Faber PW, van Rooij HCJ, Schipper HJ, Brinkmann AO, Trapman J. Two different, overlapping pathways of transcription are active on the TATA-less human androgen receptor promoter. The role of Spl. J. Biol. Chem. 1993; 268: 9296-301.
22. Saffer JD, Jackson SP, Annarella MB. Developmental expression of Sp1 in the mouse. Mol. Cell Biol. 1991; 11: 2189-99.
23. Resnick N, Collins T, Atkinson W, Bonthron DT, Dewey CF Jr, Gimbrone MA Jr. Platelet-derived growth factor B chain promoter contains a cis-acting fluid shear-stress-responsive element. Proc. Natl Acad. Sci. USA, 1993; 90: 4591-5.
24. Robinson LJ, Weremowicz S, Morton CC, Michel T. Isolation and chromosomal localization of the human endothelial nitric oxide synthase (NOS3) gene. Genomics 1994; 19: 350-7.
25. Ohara Y, Sayegh HS, Yamin JJ, Harrison DG. Regulation of endothelial nitric oxide synthase by protein kinase C. Hypertension 1995; 25: 415-20.
26. Leegwater PAJ, van Driel W, van der Viet PC. Recognition site of nuclear factor I, a sequence-specific DNA-binding protein for HeLa cells that stimulates adenovirus DNA replication. EMBO J. 1985; 4: 115-1521.
27. Zhang X, Miskimins R. Binding at an NF1 site is modulated by cyclic AMP-dependent activation of myelin basic protein gene expression. J. Neurochem. 1993; 60: 2010-17.
28. Rossi P, Karsenty G, Roberts AB, Roche NS, Sporn MB, de Crombrugghe B. A nuclear factor 1 binding site mediates the transcriptional activation of a type 1 collagen promoter by transforming growth factor-β. Cell 1988; 52: 405-14.
29. Inoue N, Venema RC, Sayegh HS, Murphy TJ, Harrison DG. Molecular regulation of the endothelial cell nitric oxide synthase by transforming growth factor β-1. Arterioscler. Thromb. Vasc. Biol. 1995; 15: 1255-61.
30. Lefer AM, Tsao P, Aoki N, Palladino MA Jr. Mediation of cardioprotection by transforming growth factor-beta. Science 1990; 249: 61-4.
31. Gamble JR, Vadas MA. Endothelial adhesiveness for blood neutrophils is inhibited by transforming growth factor-beta. Science 1988; 242: 97-9.
32. Kubes P, Suzuki M, Granger DN. Nitric oxide: An endogenous modulator of leukocyte adhesion. Proc. Natl Acad. Sci. USA 1991; 88: 4651-5.
33. Assoian RK, Sporn MB. Type beta transforming growth factor in human platelets: Release during platelet degranulation and action on vascular smooth muscle cells. J. Cell Biol. 1986; 102: 1217-23.
34. Kato S, Tora L, Yamauchi J, Masushige S, Bellard M, Chambon P. A far upstream estrogen response element of the ovalbumin gene contains several half-palindromic 5′-TGACC-3′ motifs acting synergistically. Cell 1992; 68: 731-42.
35. Augereau P, Miralles F, Cavailles V, Gaudelet C, Parker M, Rochefort H. Characterization of the proximal estrogen-responsive element of human cathepsin D gene. Mol. Endocrinol. 1994; 8: 693-703.
36. Myers PR, Minor RL Jr, Guerra R Jr, Bates JN, Harrison DG. The vasorelaxant properties of the endothelium-derived relaxing factor more closely resemble S-nitrosocysteine than nitric oxide. Nature 1990; 345: 161-3.